Human aldose reductase (ALR2) has evolved as a promising therapeutic target for the treatment of diabetic long-term complications. The binding site of this enzyme possesses two main subpockets: the catalytic anion-binding site and the hydrophobic specificity pocket. The latter can be observed in the open or closed state, depending on the bound ligand. Thus, it exhibits a pronounced capability for induced-fit adaptations, whereas the catalytic pocket exhibits rigid properties throughout all known crystal structures. Here, we determined two ALR2 crystal structures at 1.55 and 1.65 A resolution, each complexed with an inhibitor of the recently described naphtho[1,2-d]isothiazole acetic acid series. In contrast to the original design hypothesis...
Aldose reductase reduces glucose to sorbitol. It plays a key role in many of the complications arisi...
Aldose reductase (ALR2) is a critical enzyme in the development of the major complications of diabet...
Aldose reductase, the first and rate-limiting enzyme of the polyol pathway, is a target for drug des...
The TIM-barrel folded enzyme Aldose reductase (ALR2) is a valuable model system to study structural ...
AbstractBackground: Aldose reductase (AR) is an NADPH-dependent enzyme implicated in long-term diabe...
International audienceInhibition of human aldose reductase (ALR2) evolved as a promising therapeutic...
Rational drug design for flexible proteins like human aldose reductase comprises special challenges ...
The X-ray crystal structure of human aldose reductase (ALR2) in complex with the inhibitor IDD552 wa...
Aldose reductase (ALR2) is a target enzyme for the treatment of diabetic complications. Owing to the...
The inhibition of aldose reductase (AR) provides an interesting strategy to prevent the complication...
International audienceAldose reductase, a monomeric NADPH-dependent oxidoreductase, catalyzes the re...
Human aldo-keto reductase 1B10 (AKR1B10) is overexpressed in many cancer types and is involved in ch...
This study reports a molecular dynamics (MD) investigation on the structure of aldose reductase (ALR...
Insights into the thermodynamic and kinetic signature of the transient opening of a protein-binding ...
The relative binding affinities to human aldose reductase (ALR2) of three new 7-hydroxy-2-benzyl-4H-...
Aldose reductase reduces glucose to sorbitol. It plays a key role in many of the complications arisi...
Aldose reductase (ALR2) is a critical enzyme in the development of the major complications of diabet...
Aldose reductase, the first and rate-limiting enzyme of the polyol pathway, is a target for drug des...
The TIM-barrel folded enzyme Aldose reductase (ALR2) is a valuable model system to study structural ...
AbstractBackground: Aldose reductase (AR) is an NADPH-dependent enzyme implicated in long-term diabe...
International audienceInhibition of human aldose reductase (ALR2) evolved as a promising therapeutic...
Rational drug design for flexible proteins like human aldose reductase comprises special challenges ...
The X-ray crystal structure of human aldose reductase (ALR2) in complex with the inhibitor IDD552 wa...
Aldose reductase (ALR2) is a target enzyme for the treatment of diabetic complications. Owing to the...
The inhibition of aldose reductase (AR) provides an interesting strategy to prevent the complication...
International audienceAldose reductase, a monomeric NADPH-dependent oxidoreductase, catalyzes the re...
Human aldo-keto reductase 1B10 (AKR1B10) is overexpressed in many cancer types and is involved in ch...
This study reports a molecular dynamics (MD) investigation on the structure of aldose reductase (ALR...
Insights into the thermodynamic and kinetic signature of the transient opening of a protein-binding ...
The relative binding affinities to human aldose reductase (ALR2) of three new 7-hydroxy-2-benzyl-4H-...
Aldose reductase reduces glucose to sorbitol. It plays a key role in many of the complications arisi...
Aldose reductase (ALR2) is a critical enzyme in the development of the major complications of diabet...
Aldose reductase, the first and rate-limiting enzyme of the polyol pathway, is a target for drug des...